US20070086954A1
(en)
*
|
1998-11-23 |
2007-04-19 |
Miller Christopher C |
Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
|
US20040077702A1
(en)
*
|
2001-09-14 |
2004-04-22 |
Wen-Mei Fu |
Treatment of nuerodegenerative diseases
|
US7799832B2
(en)
*
|
2003-10-23 |
2010-09-21 |
Valeant Pharmaceuticals North America |
Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
|
DE602005023489D1
(en)
*
|
2004-06-23 |
2010-10-21 |
Neurotec Pharma S L |
COMPOSITION FOR USE IN THE DIAGNOSIS OF ACUTE INJURIES OF THE CENTRAL NERVOUS SYSTEM
|
WO2006000607A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Neurotec Pharma, S.L. |
Compounds for the treatment of inflammation of the central nervous system
|
AR050084A1
(en)
*
|
2004-07-27 |
2006-09-27 |
Novartis Ag |
BENCIMIDAZOLONE DERIVATIVES AS HSP90 INHIBITORS
|
DK1781265T3
(en)
*
|
2004-08-25 |
2010-08-02 |
Essentialis Inc |
Pharmaceutical formulations of potassium ATP channel openers and applications thereof
|
EP1850852A4
(en)
*
|
2005-02-22 |
2009-11-18 |
Cedars Sinai Medical Center |
Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
|
WO2007002285A2
(en)
*
|
2005-06-21 |
2007-01-04 |
The Trustees Of The University Of Pennsylvania |
Methods for treating neurological and psychiatric conditions
|
DE102005047946A1
(en)
*
|
2005-10-06 |
2007-05-03 |
Bayer Healthcare Ag |
Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases
|
EP1973948B1
(en)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
TW200732305A
(en)
*
|
2005-12-23 |
2007-09-01 |
Yung Shin Pharmaceutical Ind |
Cancer chemotherapy
|
AU2006335153B2
(en)
*
|
2006-01-05 |
2012-03-15 |
Essentialis, Inc. |
Salts of potassium ATP channel openers and uses thereof
|
WO2007112367A2
(en)
*
|
2006-03-27 |
2007-10-04 |
Portola Pharmaceuticals, Inc. |
Potassium channel modulators and platelet procoagulant activity
|
WO2007131133A2
(en)
|
2006-05-04 |
2007-11-15 |
Genentech, Inc. |
Methods and compositions relating to zpa polypeptides
|
US7960436B2
(en)
*
|
2006-06-05 |
2011-06-14 |
Valeant Pharmaceuticals International |
Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
|
KR20170098978A
(en)
|
2006-07-14 |
2017-08-30 |
에이씨 이뮨 에스.에이. |
Humanized antibody against amyloid beta
|
WO2008011348A2
(en)
|
2006-07-14 |
2008-01-24 |
Ac Immune S.A. |
Humanized antibody against amyloid beta
|
US20080045534A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Valeant Pharmaceuticals North America |
Derivatives of 1,3-diamino benzene as potassium channel modulators
|
US8993593B2
(en)
*
|
2006-08-23 |
2015-03-31 |
Valeant Pharmaceuticals International |
N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
|
US8293911B2
(en)
*
|
2006-08-23 |
2012-10-23 |
Valeant Pharmaceuticals International |
Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
|
US8722929B2
(en)
*
|
2006-10-10 |
2014-05-13 |
Valeant Pharmaceuticals International |
N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
|
CN101578259A
(en)
*
|
2006-11-28 |
2009-11-11 |
威朗国际制药公司 |
1,4 diamino bicyclic retigabine analogues as potassium channel modulators
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
CN103071154A
(en)
|
2007-04-13 |
2013-05-01 |
千年药品公司 |
Combination anticoagulant therapy with a compound that acts as a factor XA inhibitor
|
RS53793B1
(en)
|
2007-06-12 |
2015-06-30 |
Ac Immune S.A. |
Humanized antibodies to amyloid beta
|
EP2170953B1
(en)
|
2007-06-12 |
2015-07-15 |
AC Immune S.A. |
Monoclonal anti beta amyloid antibody
|
US8367684B2
(en)
*
|
2007-06-13 |
2013-02-05 |
Valeant Pharmaceuticals International |
Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
|
CN101795691A
(en)
*
|
2007-07-02 |
2010-08-04 |
伊森舍丽斯有限公司 |
Salts of potassium atp channel openers and uses thereof
|
US8563566B2
(en)
|
2007-08-01 |
2013-10-22 |
Valeant Pharmaceuticals International |
Naphthyridine derivatives as potassium channel modulators
|
US7786146B2
(en)
*
|
2007-08-13 |
2010-08-31 |
Valeant Pharmaceuticals International |
Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
|
CA2701790A1
(en)
|
2007-10-05 |
2009-04-16 |
Ac Immune S.A. |
Use of humanized anti-beta-amyloid antibody in ocular diseases
|
TWI468417B
(en)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
Anti-vegf antibodies
|
JP5986745B2
(en)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカAcademia Sinica |
Glycan arrays on PTFE-like aluminum-coated glass slides and related methods
|
KR102100066B1
(en)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
Immunoglobulin variants and uses thereof
|
KR20110081862A
(en)
|
2008-10-22 |
2011-07-14 |
제넨테크, 인크. |
Modulation of axon degeneration
|
US20120009182A1
(en)
|
2008-12-23 |
2012-01-12 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
BR112012009257A2
(en)
|
2009-10-22 |
2016-11-22 |
Genentech Inc |
axon degeneration modulation.
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
SG187173A1
(en)
|
2010-07-30 |
2013-02-28 |
Ac Immune Sa |
Safe and functional humanized anti beta-amyloid antibody
|
WO2012020124A1
(en)
|
2010-08-12 |
2012-02-16 |
Ac Immune S.A. |
Vaccine engineering
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
DK2625198T3
(en)
|
2010-10-07 |
2015-09-28 |
Ac Immune Sa |
Antibodies that recognize the phosphorylated tau
|
US9687447B2
(en)
|
2010-10-26 |
2017-06-27 |
Ac Immune S.A. |
Method for preparing liposome-based constructs
|
US20120171120A1
(en)
|
2010-11-30 |
2012-07-05 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
CN104080806B
(en)
|
2011-10-07 |
2018-01-19 |
Ac免疫有限公司 |
Identify Tau phosphorylation specific antibody
|
EP2776047A4
(en)
|
2011-11-07 |
2015-07-22 |
Gen Hospital Corp |
Treatment of red blood cells
|
MX356800B
(en)
|
2012-04-05 |
2018-06-13 |
Ac Immune Sa |
Humanized tau antibody.
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
AU2013266398A1
(en)
|
2012-05-22 |
2015-01-22 |
Genentech, Inc. |
N-substituted benzamides and their use in the treatment of pain
|
MX2015000164A
(en)
|
2012-07-06 |
2015-08-12 |
Genentech Inc |
N-substituted benzamides and methods of use thereof.
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
EP2888238A4
(en)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
WO2014049047A1
(en)
|
2012-09-27 |
2014-04-03 |
F. Hoffmann-La Roche Ag |
Substituted sulfonamide compounds
|
BR112015016395A2
(en)
|
2013-01-18 |
2017-07-11 |
Hoffmann La Roche |
3-substituted pyrazoles and use as dlk inhibitors
|
RU2015143906A
(en)
|
2013-03-14 |
2017-04-18 |
Дженентек, Инк. |
SUBSTITUTED TRIAZOLOPYRIDINES AND WAYS OF THEIR APPLICATION
|
EP2970452A2
(en)
|
2013-03-15 |
2016-01-20 |
AC Immune S.A. |
Anti-tau antibodies and methods of use
|
KR20160002850A
(en)
|
2013-05-01 |
2016-01-08 |
에프. 호프만-라 로슈 아게 |
C-linked heterocycloalkyl substituted pyrimidines and their uses
|
PE20200447A1
(en)
|
2013-05-01 |
2020-02-28 |
Hoffmann La Roche |
BIHETEROARIL COMPOUNDS AND USES OF THEM
|
US20140350097A1
(en)
*
|
2013-05-23 |
2014-11-27 |
Medinox,Inc. |
Treatment of hypotension associated with hemodialysis
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
JP2016532673A
(en)
|
2013-10-11 |
2016-10-20 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
|
MX2016008110A
(en)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Pyrazole derivatives and uses thereof as inhibitors of dlk.
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(en)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
CN106415244B
(en)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
Reactive marker compounds and uses thereof
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
KR102512592B1
(en)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
Anti-her2 glycoantibodies and uses thereof
|
KR102576850B1
(en)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
Fucosidase from bacteroides and methods using the same
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
AU2015267044A1
(en)
|
2014-05-28 |
2016-12-15 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
CN106715418A
(en)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
Therapeutic compounds and methods of use thereof
|
CN107001404B
(en)
|
2014-09-08 |
2021-06-29 |
中央研究院 |
Activation of human iNKT cells using glycolipids
|
RU2730668C2
(en)
|
2014-11-19 |
2020-08-24 |
Аксон Ньюросайенс Се |
Humanised tau antibodies in alzheimer disease
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
JP2018510844A
(en)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカAcademia Sinica |
Cancer marker and method of use thereof
|
DK3250590T3
(en)
|
2015-01-30 |
2021-10-18 |
Academia Sinica |
Compositions and Methods relating to universal glycoforms for enhanced anti-SSEA4 antibody efficacy
|
JP2018512597A
(en)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
Mutant smoothened and method of using the same
|
CN107406462B
(en)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
Tricyclic DLK inhibitors and uses thereof
|
CR20170591A
(en)
|
2015-05-22 |
2018-05-07 |
Genentech Inc |
BENZAMIDS REPLACED AND METHODS TO USE THEM
|
CN108137477A
(en)
|
2015-08-27 |
2018-06-08 |
基因泰克公司 |
Therapeutic compounds and its application method
|
JP2018532990A
(en)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
Glycan arrays and methods of use
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP2019515876A
(en)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
Methods for module synthesis of N-glycans and their arrays
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436482A4
(en)
|
2016-03-29 |
2020-03-11 |
OBI Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
CN109476628B
(en)
|
2016-07-20 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
Sulfonylcycloalkylamide compounds as TRPA1 modulators
|
JP7043483B2
(en)
|
2016-07-20 |
2022-03-29 |
エフ.ホフマン-ラ ロシュ アーゲー |
Bicyclic proline compound
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
US11304963B2
(en)
*
|
2016-07-29 |
2022-04-19 |
Biogen Chesapeake Llc |
Methods of medical treatment with SUR1-TRPM4 channel inhibitors
|
EP3497093B1
(en)
|
2016-08-12 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Sulfonyl pyridyl trp inhibitors
|
JP7213549B2
(en)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
Antibodies, Binding Fragments, and Methods of Use
|
WO2018073193A1
(en)
|
2016-10-17 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Bicyclic pyridone lactams and methods of use thereof
|
US11000601B2
(en)
|
2016-11-21 |
2021-05-11 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
TW201831477A
(en)
|
2016-11-28 |
2018-09-01 |
瑞士商赫孚孟拉羅股份公司 |
Oxadiazolone transient receptor potential channel inhibitors
|
TW201831478A
(en)
|
2016-12-02 |
2018-09-01 |
瑞士商赫孚孟拉羅股份公司 |
Bicyclic amide compounds and methods of use thereof
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
CN110461838B
(en)
|
2017-03-07 |
2022-05-06 |
豪夫迈·罗氏有限公司 |
Oxadiazole transient receptor potential channel inhibitors
|
US10793550B2
(en)
|
2017-03-24 |
2020-10-06 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
KR20200030558A
(en)
|
2017-07-14 |
2020-03-20 |
에프. 호프만-라 로슈 아게 |
Bicyclic ketone compounds and methods of use
|
CA3078653A1
(en)
|
2017-10-11 |
2019-04-18 |
F. Hoffmann-La Roche Ag |
Bicyclic compounds for use as rip1 kinase inhibitors
|
CR20200168A
(en)
|
2017-10-31 |
2020-07-12 |
Hoffmann La Roche |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
BR112020010903A2
(en)
|
2017-11-30 |
2020-11-17 |
Hanmi Pharm. Co., Ltd. |
compound, salt of a compound of formula (I), pharmaceutical composition, use of a pharmaceutical composition, use of a compound, method of preparing a crystalline form of the salt
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
US11028075B2
(en)
|
2018-02-26 |
2021-06-08 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
WO2019191702A1
(en)
|
2018-03-30 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
Substituted hydro-pyrido-azines as sodium channel inhibitors
|
CN112074519A
(en)
|
2018-04-20 |
2020-12-11 |
豪夫迈·罗氏有限公司 |
N- [ 4-oxo-2, 3-dihydro-1, 5-benzoxazepin-3-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-B ] pyrazole-2-carboxamide derivatives and related compounds as RIP1 kinase inhibitors for the treatment of e.g. Irritable Bowel Syndrome (IBS)
|
TW202003490A
(en)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use thereof
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
TW202024023A
(en)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
Therapeutic compounds and methods of use
|
JP2022516651A
(en)
|
2019-01-11 |
2022-03-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Bicyclic pyrrorotriazole ketone compounds and their usage
|
MX2022005775A
(en)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Therapeutic compounds and methods of use.
|
WO2021110995A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
JP2023544037A
(en)
|
2020-10-02 |
2023-10-19 |
ジェネンテック, インコーポレイテッド |
Methods for preparing biheteroaryl compounds and their crystalline forms
|
EP4229082A1
(en)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN114452404B
(en)
*
|
2021-12-14 |
2023-09-08 |
中山大学附属第三医院(中山大学肝脏病医院) |
Vesicle with anchoring and charge overturning functions and preparation and application thereof
|
TW202342519A
(en)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|